- Home
- Search
- Tools
- CME
- Help & Feedback
- About epocrates
- Business Solutions
Highlights & Basics
- Psoriatic arthritis (PsA) is a heterogeneous disease with multiple clinical manifestations including peripheral arthritis, spondyloarthritis, dactylitis, enthesitis, and skin and nail psoriasis.
- PsA occurs in around 25% of patients with psoriasis. Arthritis may develop before skin symptoms.
- Distinguished from rheumatoid arthritis by the pattern of joint involvement, and the presence of psoriatic disease-specific manifestations including dactylitis, enthesitis, nail psoriasis, and spondyloarthritis. Most people with PsA have seronegative arthritis.
- Management involves the use of nonsteroidal anti-inflammatory drugs, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), biologic agents, targeted DMARDs, and supportive measures, depending on clinical presentation and disease severity.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Citations
Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5-32.[Abstract][Full Text]
Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-12.[Abstract][Full Text]
Coates LC, Soriano ER, Corp N, et al; GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022 Aug;18(8):465-79.[Abstract][Full Text]
1. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55-78.[Abstract]
2. Taylor W, Gladman D, Helliwell P, et al; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-73.[Abstract][Full Text]
3. Olivieri I, Padula A, D'Angelo S, et al. Psoriatic arthritis sine psoriasis. J Rheumatol Suppl. 2009 Aug;83:28-9.[Abstract][Full Text]
4. Poddubnyy D, Jadon DR, Van den Bosch F, et al. Axial involvement in psoriatic arthritis: an update for rheumatologists. Semin Arthritis Rheum. 2021 Aug;51(4):880-7.[Abstract][Full Text]
5. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015 Nov;41(4):545-68.[Abstract][Full Text]
6. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019 Jan;80(1):251-65.e19.[Abstract]
7. Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009 Feb 15;61(2):233-9.[Abstract]
8. Wilson FC, Icen M, Crowson CS, et al. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009 Feb;36(2):361-7.[Abstract]
9. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017 Mar 9;376(10):957-70.[Abstract]
10. Furst DE, Belasco J, Louie JS. Genetic and inflammatory factors associated with psoriatic arthritis: relevance to diagnosis and management. Clin Immunol. 2019 May;202:59-75.[Abstract]
11. Patrick MT, Stuart PE, Raja K, et al. Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. Nat Commun. 2018 Oct 9;9(1):4178.[Abstract][Full Text]
12. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018 Jun 2;391(10136):2273-84.[Abstract]
13. Njobvu P, McGill P. Psoriatic arthritis and human immunodeficiency virus infection in Zambia. J Rheumatol. 2000 Jul;27(7):1699-702.[Abstract]
14. Thorarensen SM, Lu N, Ogdie A, et al. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Ann Rheum Dis. 2017 Mar;76(3):521-5.[Abstract]
15. Thrastardottir T, Love TJ. Infections and the risk of psoriatic arthritis among psoriasis patients: a systematic review. Rheumatol Int. 2018 Aug;38(8):1385-97.[Abstract]
16. Eder L, Law T, Chandran V, et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (Hoboken). 2011 Aug;63(8):1091-7.[Abstract][Full Text]
17. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010 May;34(3):J314-21.[Abstract]
18. Chhabra S, Dogra S, Sharma K, et al. Recent update on immunopathogenesis of psoriasis. Indian J Dermatol. 2022 Jul-Aug;67(4):360-73.[Abstract][Full Text]
19. Penkava F, Velasco-Herrera MDC, Young MD, et al. Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis. Nat Commun. 2020 Sep 21;11(1):4767.[Abstract][Full Text]
20. Steel KJA, Srenathan U, Ridley M, et al. Polyfunctional, proinflammatory, tissue-resident memory phenotype and function of synovial interleukin-17A+CD8+ T cells in psoriatic arthritis. Arthritis Rheumatol. 2020 Mar;72(3):435-47.[Abstract][Full Text]
21. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012 Jan;359(1-2):419-29.[Abstract]
22. Raychaudhuri SK, Raychaudhuri SP. SCID mouse model of psoriasis: a unique tool for drug development of autoreactive T-cell and th-17 cell-mediated autoimmune diseases. Indian J Dermatol. 2010 Apr-Jun;55(2):157-60.[Abstract][Full Text]
23. Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther. 2009;11(1):214.[Abstract][Full Text]
24. Olivieri I, Padula A, D'Angelo S, et al. Role of trauma in psoriatic arthritis. J Rheumatol. 2008 Nov;35(11):2085-7.[Abstract]
25. Perez-Chada LM, Haberman RH, Chandran V, et al. Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. Nat Rev Rheumatol. 2021 Apr;17(4):238-43.[Abstract][Full Text]
26. Alenius GM, Stenberg B, Stenlund H, et al. Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol. 2002 Dec;29(12):2577-82.[Abstract][Full Text]
27. Dominguez PL, Husni ME, Holt EW, et al. Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire. Arch Dermatol Res. 2009 Sep;301(8):573-9.[Abstract][Full Text]
28. Ibrahim GH, Buch MH, Lawson C, et al. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009 May-Jun;27(3):469-74.[Abstract][Full Text]
29. Khraishi M, Mong J, Mugford G, et al. The electronic Psoriasis and Arthritis Screening Questionnaire (ePASQ): a sensitive and specific tool to diagnose psoriatic arthritis patients. J Cutan Med Surg. 2011 May-Jun;15(3):143-9.[Abstract]
30. Gladman DD, Schentag CT, Tom BD, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis. 2009 Apr;68(4):497-501.[Abstract]
31. Tom BD, Chandran V, Farewell VT, et al. Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2). J Rheumatol. 2015 May;42(5):841-6.[Abstract][Full Text]
32. Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol. 2016 Apr;68(4):915-23.[Abstract][Full Text]
33. Chandran V, O'Shea FD, Schentag CT, et al. Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis. J Rheumatol. 2007 Dec;34(12):2463-5.[Abstract]
34. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr;80(4):1073-113.[Abstract][Full Text]
35. Raychaudhuri SK, Chatterjee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010 Aug;8(4):331-4.[Abstract][Full Text]
36. Raychaudhuri SP. Comorbidities of psoriatic arthritis - metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012 Feb;39(2):437-40.[Abstract][Full Text]
37. Machado PM, Raychaudhuri SP. Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2014 Oct;28(5):711-28.[Abstract]
38. Raychaudhuri SP, Wilken R, Sukhov AC, et al. Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun. 2017 Jan;76:21-37.[Abstract]
39. Gould D, Kelly D, Goldstone L, et al. Examining the validity of pressure ulcer risk assessment scales: developing and using illustrated patient simulations to collect the data. INFORMATION POINT: Visual Analogue Scale (VAS). J Clin Nurs. 2001 Sep;10(5):697-706.[Abstract]
40. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003 Jun 9;1:20.[Abstract][Full Text]
41. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010 Jan;69(1):48-53.[Abstract]
42. Chew E, Perin J, Grader-Beck T, et al. Measurement of minimal disease activity in psoriatic arthritis using the Patient-Reported Outcomes Measurement Information System-Physical Function or the Health Assessment Questionnaire Disability Index. Arthritis Care Res (Hoboken). 2022 Jan;74(1):151-60.[Abstract][Full Text]
43. Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med. 1987 Feb;62(238):127-41.[Abstract]
44. Merola JF, Espinoza LR, Fleischmann R. Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open. 2018;4(2):e000656.[Abstract][Full Text]
45. Helliwell PS, Porter G, Taylor WJ, et al. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. Ann Rheum Dis. 2007 Jan;66(1):113-7.[Abstract]
46. Lindqvist UR, Alenius GM, Husmark T, et al. The Swedish early psoriatic arthritis register, 2-year follow-up: a comparison with early rheumatoid arthritis. J Rheumatol. 2008 Apr;35(4):668-73.[Abstract]
47. Diaz P, Feld J, Eshed I, et al. Characterising axial psoriatic arthritis: correlation between whole spine MRI abnormalities and clinical, laboratory and radiographic findings. RMD Open. 2022 Jan;8(1):e002011.[Abstract][Full Text]
48. Jadon DR, Sengupta R, Nightingale A, et al. Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis. 2017 Apr;76(4):701-7.[Abstract][Full Text]
49. Wendling D, Prati C, Saraux A, et al. Dactylitis in early spondyloarthritis. Data from the prospective French national cohort DESIR. Joint Bone Spine. 2020 Oct;87(5):497-9.[Abstract]
50. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5-32.[Abstract][Full Text]
51. Perez-Chada LM, Merola JF. Comorbidities associated with psoriatic arthritis: review and update. Clin Immunol. 2020 May;214:108397.[Abstract]
52. Zohar A, Cohen AD, Bitterman H, et al. Gastrointestinal comorbidities in patients with psoriatic arthritis. Clin Rheumatol. 2016 Nov;35(11):2679-84.[Abstract]
53. Alenius GM, Berglin E, Rantapää Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis. 2006 Mar;65(3):398-400.[Abstract][Full Text]
54. Toussi A, Maverakis N, Le ST, et al. Updated therapies for the management of psoriatic arthritis. Clin Immunol. 2020 Nov;220:108536.[Abstract]
55. Gladman DD, Hing EN, Schentag CT, et al. Remission in psoriatic arthritis. J Rheumatol. 2001 May;28(5):1045-8.[Abstract]
56. Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003 Dec;42(12):1460-8.[Abstract][Full Text]
57. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, et al. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis. 2003 Jan;62(1):68-70.[Abstract][Full Text]
58. Brockbank JE, Stein M, Schentag CT, et al. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005 Feb;64(2):188-90.[Abstract][Full Text]
59. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015 Dec 19;386(10012):2489-98.[Abstract][Full Text]
60. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-12.[Abstract][Full Text]
61. Coates LC, Soriano ER, Corp N, et al; GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022 Aug;18(8):465-79.[Abstract][Full Text]
62. Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. [Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.][Abstract][Full Text]
63. Menon K, Van Voorhees AS, Bebo BF Jr, et al. National Psoriasis Foundation. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010 Feb;62(2):291-9.[Abstract]
64. Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford). 2010 Jul;49(7):1367-73.[Abstract][Full Text]
65. Pujades-Rodriguez M, Morgan AW, Cubbon RM, et al. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study. PLoS Med. 2020 Dec;17(12):e1003432.[Abstract][Full Text]
66. Conway R, Low C, Coughlan RJ, et al. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ. 2015 Mar 13;350:h1269.[Abstract][Full Text]
67. Wilsdon TD, Whittle SL, Thynne TR, et al. Methotrexate for psoriatic arthritis. Cochrane Database Syst Rev. 2019 Jan 18;(1):CD012722.[Abstract][Full Text]
68. Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020 Mar 1;59(suppl 1):i37-46.[Abstract][Full Text]
69. Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 2019 Jul;71(7):1112-24.[Abstract][Full Text]
70. Rahman P, Arendse R, Khraishi M, et al. Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry. BMJ Open. 2020 Aug 13;10(8):e036245.[Abstract][Full Text]
71. Bhoi P, Bessette L, Bell MJ, et al. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. BMJ Open. 2017 Sep 18;7(9):e015872.[Abstract][Full Text]
72. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006 May 17;295(19):2275-85.[Abstract]
73. McInnes IB, Behrens F, Mease PJ, et al; EXCEED Study Group. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020 May 9;395(10235):1496-505.[Abstract]
74. Mease PJ, Smolen JS, Behrens F, et al; SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020 Jan;79(1):123-31.[Abstract][Full Text]
75. Deodhar A, Helliwell PS, Boehncke WH, et al; DISCOVER-1 Study Group. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF-alpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1115-25.[Abstract]
76. Mease PJ, Rahman P, Gottlieb AB, et al; DISCOVER-2 Study Group. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1126-36.[Abstract]
77. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol. 2021 Apr;73(4):604-16.[Abstract][Full Text]
78. Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022 Mar;81(3):351-8.[Abstract][Full Text]
79. Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022 Feb;81(2):225-31.[Abstract][Full Text]
80. McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022 Mar;74(3):475-85.[Abstract][Full Text]
81. Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022 Mar;81(3):359-69.[Abstract][Full Text]
82. Bilal J, Berlinberg A, Riaz IB, et al. Risk of infections and cancer in patients with rheumatologic diseases receiving interleukin inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019 Oct 2;2(10):e1913102.[Abstract][Full Text]
83. Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015 Jul 18;386(9990):258-65.[Abstract]
84. Mease P, Gottlieb A, Heijde H, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase 3 study in psoriatic arthritis. Ann Rheum Dis. 2017 Sep;76(9):1550-1558.[Abstract][Full Text]
85. Strand V, Alemao E, Lehman T, et al. Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial. Arthritis Res Ther. 2018 Dec 6;20(1):269.[Abstract][Full Text]
86. ClinicalTrials.gov. Safety study of tofacitinib versus tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis. NCT02092467. Aug 2021 [internet publication].[Full Text]
87. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Sep 2021 [internet publication].[Full Text]
88. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 June 2021: PRAC concludes review of signal of increased risk of major cardiovascular events and cancer with Xeljanz. Jun 2021 [internet publication].[Full Text]
89. Medicines and Healthcare products Regulatory Agency. Tofacitinib (Xeljanz): new measures to minimise risk of major adverse cardiovascular events and malignancies. Oct 2021 [internet publication].[Full Text]
90. Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021 May;80(5):582-90.[Abstract][Full Text]
91. Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021 Aug;80(8):1004-13.[Abstract][Full Text]
92. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2019 Oct;71(10):1285-99.[Abstract][Full Text]
93. Mourad A, Gniadecki R. Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and metaanalysis. J Rheumatol. 2020 Jan;47(1):59-65.[Abstract][Full Text]
94. Simons N, Degboé Y, Barnetche T, et al. Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes. Clin Exp Rheumatol. 2020 May-Jun;38(3):508-15.[Abstract][Full Text]
95. Vieira-Sousa E, Alves P, Rodrigues AM, et al. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Ann Rheum Dis. 2020 Apr;79(4):490-8.[Abstract][Full Text]
96. Gladman DD, Orbai AM, Klitz U, et al. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. Arthritis Res Ther. 2019 Jan 29;21(1):38.[Abstract][Full Text]
97. Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020 Feb 8;395(10222):427-40.[Abstract]
98. Blauvelt A, Papp KA, Merola JF, et al. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. J Am Acad Dermatol. 2020 Nov;83(5):1367-74.[Abstract][Full Text]
99. Coates LC, McInnes IB, Merola JF, et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: three-year results from a phase IIb randomized controlled trial and Its open-label extension study. Arthritis Rheumatol. 2022 Dec;74(12):1959-70.[Abstract][Full Text]
100. Lebwohl M, Leonardi C, Wu JJ, et al. Two-year US pharmacovigilance report on brodalumab. Dermatol Ther (Heidelb). 2021 Feb;11(1):173-80.[Abstract][Full Text]
101. Mease PJ, Helliwell PS, Hjuler KF, et al. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis. 2021 Feb;80(2):185-93.[Abstract][Full Text]
102. Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022 Jun;81(6):815-22.[Abstract][Full Text]
103. Mease P, Helliwell P, Silwinska-Stanczyk P, et al. Efficacy and safety of the TYK2/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial. Arthritis Rheumatol. 2023 May 17;art.42519. [Epub ahead of print.][Abstract][Full Text]
104. Orvain C, Boulch M, Bousso P, et al. Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases? Arthritis Rheumatol. 2021 Nov;73(11):1954-65.[Abstract][Full Text]
105. Scher JU, Ogdie A, Merola JF, et al. Moving the goalpost toward remission: the case for combination immunomodulatory therapies in psoriatic arthritis. Arthritis Rheumatol. 2021 Sep;73(9):1574-8.[Abstract]
106. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2023 Mar;75(3):333-48.[Abstract][Full Text]
107. Krieckaert CL, van Tubergen A, Gehin JE, et al. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023 Jan;82(1):65-73.[Abstract][Full Text]
108. Nikiphorou E, Santos EJF, Marques A, et al. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Ann Rheum Dis. 2021 Oct;80(10):1278-85.[Abstract][Full Text]
109. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005 Mar;64 Suppl 2(suppl 2):ii14-7.[Abstract][Full Text]
110. Zangger P, Gladman DD, Bogoch ER. Musculoskeletal surgery in psoriatic arthritis. J Rheumatol. 1998 Apr;25(4):725-9.[Abstract]
111. Guldberg-Møller J, Cordtz RL, Kristensen LE, et al. Incidence and time trends of joint surgery in patients with psoriatic arthritis: a register-based time series and cohort study from Denmark. Ann Rheum Dis. 2019 Nov;78(11):1517-23.[Abstract][Full Text]
112. Michet CJ, Mason TG, Mazlumzadeh M. Hip joint disease in psoriatic arthritis: risk factors and natural history. Ann Rheum Dis. 2005 Jul;64(7):1068-70.[Abstract][Full Text]
113. Ali Y, Tom BD, Schentag CT, et al. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum. 2007 Aug;56(8):2708-14.[Abstract][Full Text]
114. Kerola AM, Kazemi A, Rollefstad S, et al. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology (Oxford). 2022 Nov 28;61(12):4656-66.[Abstract][Full Text]
115. Elalouf O, Muntyanu A, Polachek A, et al. Mortality in psoriatic arthritis: risk, causes of death, predictors for death. Semin Arthritis Rheum. 2020 Aug;50(4):571-5.[Abstract][Full Text]
116. Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis (PsA). Ann Rheum Dis. 2009 Jul;68(7):1131-5.[Abstract]
117. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;76(1):17-28.[Abstract][Full Text]
118. Mallbris L, Ritchlin CT, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep. 2006 Oct;8(5):355-63.[Abstract]
119. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008 Jun;58(6):1031-42.[Abstract]
120. Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013 Feb;72(2):211-6.[Abstract]
121. Lindsay K, Fraser AD, Layton A, et al. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford). 2009 May;48(5):569-72.[Abstract]
122. Montaudié H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol. 2011 May;25 Suppl 2:12-8.[Abstract]
123. Taylor WJ, Korendowych E, Nash P, et al. Drug use and toxicity in psoriatic disease: focus on methotrexate. J Rheumatol. 2008 Jul;35(7):1454-7.[Abstract]
124. Lindsay K, Gough A. Psoriatic arthritis, methotrexate and the liver are rheumatologists putting their patients at risk? Rheumatology (Oxford). 2008 Jul;47(7):939-41.[Abstract][Full Text]
125. Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol. 2010 Nov;37(11):2205-15.[Abstract]
126. Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011 Jun;64(6):1035-50.[Abstract]
127. Lortholary O, Fernandez-Ruiz M, Baddley JW, et al. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Ann Rheum Dis. 2020 Dec;79(12):1532-43.[Abstract]
128. Polachek A, Muntyanu A, Lee KA, et al. Malignancy in psoriatic disease: results from prospective longitudinal cohorts. Semin Arthritis Rheum. 2021 Feb;51(1):144-9.[Abstract]
129. Ogdie A, Harter L, Shin D, et al. The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. Ann Rheum Dis. 2017 May;76(5):882-5.[Abstract][Full Text]
130. Kathuria P, Gordon KB, Silverberg JI. Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures. J Am Acad Dermatol. 2017 Jun;76(6):1045-53.e3.[Abstract][Full Text]
131. Damian AC, Colaco K, Rohekar S, et al. The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. Semin Arthritis Rheum. 2021 Jun;51(3):547-52.[Abstract]
132. Farber EM, Raychaudhuri SP. Concept of total care: a third dimension in the treatment of psoriasis. Cutis. 1997 Jan;59(1):35-9.[Abstract]
133. Gossec L, de Wit M, Kiltz U, et al; EULAR PsAID Taskforce. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014 Jun;73(6):1012-9.[Abstract][Full Text]
134. National Institute for Health and Care Excellence. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. Aug 2010 [internet publication].[Full Text]
